HRGN · XBRL financial data

Harvard Apparatus Regenerative Technology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (HRGN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	40	63*	57	56	59	year only	45	317	123	219*	226	414
Cost of revenue	—	year only	12	13	70	year only	33	302	112	199*	206	391
Research and development	339	648*	840	642	557	271*	601	697	655	700*	563	948
General and administrative	1,169	1,136*	1,111	1,685	1,148	1,078*	1,071	1,151	1,045	986*	1,045	751
Total operating expenses	1,664	1,891*	2,078	2,537	1,918	—	—	—	—	—	—	—
Operating income (loss)	(1,624)	(1,828)*	(2,021)	(2,481)	(1,859)	(1,365)*	(1,670)	(1,833)	(1,714)	(1,698)*	(1,606)	(1,692)
Interest income	18	5*	0	0	0	32*	13	7	11	6*	2	0
Interest expense	—	year only	9	17	11	2*	2	3	2	1*	2	8
Other income (expense)	14	(53)*	(9)	(17)	(1)	27*	—	—	—	—	—	—
Income tax expense (benefit)	—	—	—	—	—	year only	0	0*	—	year only	0	0*
Net income (loss)	(1,615)	(1,826)*	(2,030)	(2,498)	(1,860)	(1,344)*	(1,659)	(1,823)	(1,700)	(1,687)*	(1,601)	(1,695)
Earnings per share, basic USD per share	(0.12)	(0.13)*	(0.15)	(0.18)	(0.12)	(0.08)*	(0.10)	(0.11)	(0.10)	(0.10)*	(0.09)	(0.10)
Earnings per share, diluted USD per share	(0.12)	(0.13)*	(0.15)	(0.18)	(0.12)	—	—	—	—	—	—	—
Weighted average shares, basic thousands of shares	13,882	13,925*	13,947	14,259	15,018	15,919*	15,919	15,919	17,033	17,178*	17,581	17,581
Weighted average shares, diluted thousands of shares	13,882	13,925*	13,947	14,259	15,018	—	—	—	—	—	—	—

Fiscal quarters (HRGN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	269	432	272	139	3,593	2,486	1,728	786	1,319	1,352	419	351
Short-term investments	1,232	1,200	—	—	—	—	—	—	—	—	—	—
Accounts receivable	3	4	7	—	1	231	4	5	3	16	16	9
Inventory	56	50	44	60	113	80	48	27	22	16	15	0
Prepaid and other current assets	120	87	135	114	146	347	432	246	230	427	405	346
Total current assets	1,890	783	617	656	3,974	3,234	2,302	1,117	1,627	1,829	873	789
Property and equipment, net	31	25	19	14	13	11	9	8	7	6	5	4
Right-of-use asset	103	48	21	68	318	293	270	245	221	195	168	141
Total assets	3,782	2,614	2,415	1,730	5,311	4,442	3,415	2,137	2,546	2,677	1,798	1,685
Accounts payable	424	445	890	752	507	452	455	352	313	454	239	757
Total current liabilities	1,055	968	2,240	1,992	1,247	1,021	1,195	1,231	876	1,534	1,651	3,042
Lease liability, non-current	11	0	—	28	224	199	172	145	116	86	55	22
Total liabilities	1,066	968	—	2,020	1,471	1,220	1,367	1,376	992	1,620	1,706	3,064
Accumulated deficit	(90,130)	(91,956)	(93,986)	(96,484)	(98,344)	(99,688)	(101,347)	(103,170)	(104,870)	(106,557)	(108,158)	(109,853)
Total stockholders' equity	2,716	1,646	175	(290)	3,840	3,222	2,048	761	1,554	1,057	92	(1,379)
Total liabilities and equity	3,782	2,614	2,415	1,730	5,311	4,442	3,415	2,137	2,546	2,677	1,798	1,685
Common shares outstanding (cover page) thousands of shares	13,947	13,947	14,315	14,530	15,919	15,919	15,919	17,169	17,169	17,581	17,581	17,581

Fiscal quarters (HRGN's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,615)	(1,826)*	(2,030)	(2,498)	(1,860)	(1,344)*	(1,659)	(1,823)	(1,700)	(1,687)*	(1,601)	(1,695)
Stock-based compensation	535*	607*	560	572*	562*	708*	485	537*	495*	493*	632	223*
Net cash from operating activities	(3,162)*	(1,218)*	(960)	(1,293)*	(1,474)*	(1,125)*	(758)	(941)*	(1,465)*	(664)*	(937)	(569)*
Purchases of property and equipment	0*	0*	—	—	—	year only	—	—	—	—	—	—
Net cash from investing activities	1,291*	1,232*	—	—	—	year only	—	—	—	—	—	—
Proceeds from issuing common stock	0*	0*	—	—	5,000*	0*	—	—	2,000*	700*	—	—
Net cash from financing activities	0*	149*	801	1,181*	4,930*	0*	0	0*	2,000*	700*	—	—
Net change in cash	(1,871)*	163*	(160)	(133)*	3,454*	(1,107)*	(758)	(942)*	533*	33*	(933)	(68)*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Harvard Apparatus Regenerative Technology	351	414	(569)*	17.6M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
RetinalGenix Technologies	27	not reported	(137)*	18.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Beyond Air	5,509	1,768	(4,946)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
NutriBand	3,422	438	(585)*	12.2M	—	Q2 FY27 10-QJul 31, 2026
Nexalin Technology	1,005	12	(1,802)*	22.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Iridex	4,680	12,566	174*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.